The competition for senior talent in tech‑enabled biology, spanning AI‑driven drug discovery, computational biology, digital health, and data‑rich platforms, has reached unprecedented levels. Biotech companies are now competing not only with traditional pharma, but also with Big Tech, venture‑backed software companies, and well‑capitalised platform businesses for the same scarce skillsets. The result is a global talent war, particularly at the intersection of science, data, and leadership.

Critical roles such as Chief Technology Officer, Head of Computational Biology, Principal AI Scientist, and hybrid scientific‑commercial leaders are in chronically short supply. These individuals must combine deep domain expertise with the ability to operate in fast‑moving, cross‑functional environments, something that cannot be solved through compensation alone. Purpose, platform credibility, and the quality of leadership are now decisive factors in attracting elite candidates.

At the executive level, competition has intensified further as companies seek leaders who can bridge science and scale. Boards and investors are prioritising executives who have operated across both biotech and technology ecosystems, leaders comfortable with agile development, data‑driven decision‑making, and partnering models. This has sharply increased demand for a relatively small pool of proven crossover talent.

Winning in this environment requires a far more thoughtful and proactive approach to talent strategy. Successful organisations are engaging earlier, building long‑term relationships with future leaders, and using executive search not simply to fill roles, but to shape leadership architecture ahead of growth. In today’s market, access to the right talent is not a support function, it is a core competitive advantage.